The Claim
Anti-inflammatory therapies alone are insufficient to reverse insulin resistance in visceral adipose tissue because they do not inhibit ceramide-mediated signaling pathways that maintain insulin resistance.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Treating inflammation alone does not restore normal insulin response in fat tissue around organs because the underlying problem involves ceramide signaling that continues to disrupt insulin function.
See the scientific wording
Anti-inflammatory therapies alone are insufficient to reverse insulin resistance in visceral adipose tissue because they do not address the downstream ceramide-mediated signaling that sustains resistance.
When insulin levels stay high, fat cells in the belly area start making too much ceramide, a fat molecule that blocks insulin from working properly. This causes the fat cells to stop taking in sugar, which then feeds immune cells that become more inflammatory. These immune cells release more signals that make the fat cells produce even more ceramide, creating a loop that keeps insulin resistance going. Even if inflammation is reduced, the ceramide buildup continues to block insulin, so lowering inflammation alone does not fix the problem.
What the research says
1 studyStudy: Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue
Just calming down the inflammation in fat tissue doesn’t fix insulin resistance because there’s another hidden problem inside the fat cells—too much ceramide—that keeps the resistance going. You have to fix that too.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.